Strong Domestic Operations:
Jenburkt Pharma has a strong committed team of more than 575 sales force across
India, Jenburkt promotes all its 85 brands ethically across 75,000 doctors and 50,000
chemists regularly. Backing the strong force company has more than 1000 stockists
and 25 superstockists. Jenburkt also caters to large Government, Semi-Government
Institutions, Missionary Hospitals, Public Sector Enterprises, etc.
Growing International Exports:
Currently, Jenburkt's products are being exported to 15 countries globally with
a clear focus to expand on a yearly basis. Also Jenburkt is open to partnering foreign
pharmaceutical firms to market their pharmaceutical products in India; Company is
also in search of a capable partner to market their pharmaceutical products across
the globe through which they can improve on their exports sales which constitutes
small proportion of total sales.
Strengthening the Brand:
Company is focused on strengthening their brands in their respective segments during
the last year. There is a growing trend of competition from regional companies who
operate either in a few districts or in a few states in India. This is apart from
the competition from large organizations operating in India. Neuropathy detection
camps and bone densitometry camps were carried out in various parts of the country
for detection of neuropathy and osteoporosis.. The strategy of Company is to focus
on long term therapies in acute and chronic ailments, by moving up the value chain
continuously. As a result, a few of the Company’s brands are the preferred choice
in certain segments. Company has some strong brand like CARTI SAFE FORTE (Anti Arithritic)
, POWERGESIC Tablets (Anti Inflammory Analogesic).They rank among the top five in
Quality Portfolio of Products:
Jenburkt has good health through quality products that include prescription and
over-the-counter drugs. Their prescription medicines span across various therapeutic
areas such as anti-arthritic, antimalarials, anti-osteoporotic, antibiotics, antidiabetics
and anti-inflammatory drugs and more. Hence Company has good quality of products
in their portfolio.
Strong Manufacturing Facilities:
Company has the state-of-the-art manufacturing plant at Sihor-Gujarat, in India.
The plant is modern and well-equipped with spacious operational areas having adequate
capacities for manufacturing world-class pharmaceutical and healthcare products.
Company’s plant is approved as per W.H.O Guidelines with current G.M.P requirements,
apart from approvals from various countries. Furthering the development of formulations,
Jenburkt has a Research & Development unit duly approved by the Ministry of
Science & Technology, Government of India. Hence company has strong manufacturing
facilities to cater both domestic and international market. Also Jenburkt has a
progressive lineage of manufacturing high quality formulations backed by a strong
Research & Development, Regulatory and global marketing team. The big thrust
of Jenburkt's strategy is to focus on creating a new category in the Indian and
the International pharmaceutical market vis a vis.
Recent R&D Activities:
Recently company undertook commercial scale manufacturing of Frendacid, an antacid
and antiflatulance for export market. Also Company continue to work towards formulating
new and existing molecules for domestic and international market for efficient and
cost saving drug delivery systems. Hence company is in continuous process of improving
on its product portfolio.
Last year company posted strong gross profit margins of above 67%, EBITDA margin
above 15%, PAT margins near 10% which are excellent numbers for mid cap pharma companies.
With no further capex required in next few years company can post 200 crore of sales
in next three years. Also employee cost which is 23% of total sales as on date is
expected to reduce going forward as recent capex will take place for execution hence
margins will be increased gradually in next few years. Company also pays regular
dividend every year which help them to maintain strong dividend yield of above 4%.
Company is debt free company with 16.75 crores of cash in hand.